These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 9498303)

  • 1. Matrix metalloproteinases and diseases of the CNS.
    Yong VW; Krekoski CA; Forsyth PA; Bell R; Edwards DR
    Trends Neurosci; 1998 Feb; 21(2):75-80. PubMed ID: 9498303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of membrane type-matrix metalloproteinases in the inflamed or injured central nervous system.
    Toft-Hansen H; Babcock AA; Millward JM; Owens T
    J Neuroinflammation; 2007 Sep; 4():24. PubMed ID: 17883829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain.
    Gasche Y; Soccal PM; Kanemitsu M; Copin JC
    Front Biosci; 2006 May; 11():1289-301. PubMed ID: 16368516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular matrix-remodeling metalloproteinases and infection of the central nervous system with retrovirus human T-lymphotropic virus type I (HTLV-I).
    Giraudon P; Buart S; Bernard A; Thomasset N; Belin MF
    Prog Neurobiol; 1996 Jun; 49(2):169-84. PubMed ID: 8844825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular matrix degradation by metalloproteinases and central nervous system diseases.
    Lukes A; Mun-Bryce S; Lukes M; Rosenberg GA
    Mol Neurobiol; 1999 Jun; 19(3):267-84. PubMed ID: 10495107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase-3 in the central nervous system: a look on the bright side.
    Van Hove I; Lemmens K; Van de Velde S; Verslegers M; Moons L
    J Neurochem; 2012 Oct; 123(2):203-16. PubMed ID: 22862420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system.
    Cuzner ML; Opdenakker G
    J Neuroimmunol; 1999 Feb; 94(1-2):1-14. PubMed ID: 10376931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of matrix metalloproteinases in human glioma cell lines in the presence of IL-10.
    Wagner S; Stegen C; Bouterfa H; Huettner C; Kerkau S; Roggendorf W; Roosen K; Tonn JC
    J Neurooncol; 1998 Nov; 40(2):113-22. PubMed ID: 9892093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MMPs in the central nervous system: where the good guys go bad.
    Agrawal SM; Lau L; Yong VW
    Semin Cell Dev Biol; 2008 Feb; 19(1):42-51. PubMed ID: 17646116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix Metalloproteinases, Neural Extracellular Matrix, and Central Nervous System Pathology.
    De Luca C; Papa M
    Prog Mol Biol Transl Sci; 2017; 148():167-202. PubMed ID: 28662822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinases in inflammatory demyelination: targets for treatment.
    Kieseier BC; Seifert T; Giovannoni G; Hartung HP
    Neurology; 1999 Jul; 53(1):20-5. PubMed ID: 10408531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor.
    Clements JM; Cossins JA; Wells GM; Corkill DJ; Helfrich K; Wood LM; Pigott R; Stabler G; Ward GA; Gearing AJ; Miller KM
    J Neuroimmunol; 1997 Apr; 74(1-2):85-94. PubMed ID: 9119983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis: elevated expression of matrix metalloproteinases in blood monocytes.
    Kouwenhoven M; Ozenci V; Gomes A; Yarilin D; Giedraitis V; Press R; Link H
    J Autoimmun; 2001 Jun; 16(4):463-70. PubMed ID: 11437495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential use of MMP inhibitors to treat CNS diseases.
    Yong VW
    Expert Opin Investig Drugs; 1999 Mar; 8(3):255-68. PubMed ID: 15992076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome.
    Segura AM; Luna RE; Horiba K; Stetler-Stevenson WG; McAllister HA; Willerson JT; Ferrans VJ
    Circulation; 1998 Nov; 98(19 Suppl):II331-7; discussion II337-8. PubMed ID: 9852923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Update on the Role of Matrix Metalloproteinases in the Pathogenesis of Multiple Sclerosis.
    Boziki M; Grigoriadis N
    Med Chem; 2018 Feb; 14(2):155-169. PubMed ID: 28875862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter.
    Beliën AT; Paganetti PA; Schwab ME
    J Cell Biol; 1999 Jan; 144(2):373-84. PubMed ID: 9922462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of matrix metalloproteinase activity in cancer.
    Jones JL; Walker RA
    J Pathol; 1997 Dec; 183(4):377-9. PubMed ID: 9496252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Matrix metalloproteinases and their inhibitors, modulators of neuro-immune interactions and of pathophysiological processes in the nervous system].
    Khrestchatisky M; Jourquin J; Ogier C; Charton G; Bernard A; Tremblay E; Rivera S
    J Soc Biol; 2003; 197(2):133-44. PubMed ID: 12910628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis.
    Di Girolamo N; Verma MJ; McCluskey PJ; Lloyd A; Wakefield D
    Curr Eye Res; 1996 Oct; 15(10):1060-8. PubMed ID: 8921246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.